Research Collaborations

Developing maximum potential for VHH therapeutics, our collaborations span clinical applications, machine learning and making our discovery and development more efficient.

Clinical validation

We collaborate with world leading experts to demonstrate the clinical applications of VHH.

Teaming up with Professor Martin Dyer’s lab at the University of Leicester, we’re developing novel immunotherapies for blood cancers such as multiple myeloma and diffuse large B cell lymphoma (DLBCL), potentially offering a new approach for patients with refractory cancers who have been through many rounds of treatment. Read more.

Through our collaboration with the University of Hull, we are demonstrating the use of VHH in radio imaging.

Knowledge transfer and improving efficiency

We team up with others, combining our expertise with theirs to accelerate research around shared issues and to make our discovery work harder and faster.

Through a Knowledge Transfer Partnership, we’re working with researchers at the University of Nottingham and Aston University to apply machine learning tools to our own way of working. Read more.

We are advancing  our drug discovery efforts  by using PipeBio’s bioinformatics cloud for analysing our synthetic VHH libraries. Read more.

Working with scientists at the Oncode Institute and University Medical Center Utrecht, we identified a potential VHH treatment of Wnt-hypersentive tumours. The collaboration used our fully synthetic, highly diverse LlamdA™ library to screen for Wnt pathway inhibitors using our CIS display technology. Read more.


Cost effective manufacturing solutions

We collaborate with others to make manufacturing VHH antibodies faster, easier to scale-up, cheaper and safer.

Our collaboration with Phenotypeca has shown how the yeast Saccharomyces cerevisiae can be used for faster, safer and cheaper bioproduction of high-quality mono- and multi-specific VHH antibodies. Read more.

Working alongside researchers at Queen Mary, we explored novel methods of producing antibodies that can potentially overcome the current problems associated with using E. coli. Read more.


Thank you to our funders who enable us to collaborate with universities, research institutions and companies.